Project 170324
Access to and Quality of Cardiac Care for First Nations People
Access to and Quality of Cardiac Care for First Nations People
Project Information
| Study Type: | Trial Randomized_Controlled_Trial |
| Therapeutic Area: | Infectious_Disease |
| Research Theme: | Clinical |
| Disease Area: | HIV and HSV-2 co-infection |
| Data Type: | Global |
Institution & Funding
| Principal Investigator(s): | Hemmelgarn, Brenda R |
| Co-Investigator(s): | Ahmed, Sofia B; Crowshoe, Lynden L; Faris, Peter D; Ghali, William A; Knudtson, Merril L; Manns, Braden J; Quan, Hude; Tonelli, Marcello; Zhang, Jianguo |
| Institution: | University of Calgary |
| CIHR Institute: | Indigenous Peoples' Health |
| Program: | |
| Peer Review Committee: | Aboriginal Peoples' Health |
| Competition Year: | 2008 |
| Term: | 3 yrs 0 mth |
Abstract Summary
Cardiovascular disease (CVD) is becoming more common among the First Nations population in Canada, resulting in an increasing burden of illness and death. Hospital admission rates for CVD are stable or declining for the Caucasian population, while they are steadily increasing for the First Nations population. In addition mortality secondary to CVD is also increasing in the First Nations population, with CVD the leading cause of death in this patient population. Reasons for the increasing burden of CVD among the First Nations population are not entirely clear, although factors including access to specialized cardiac care and procedures, as well as quality of cardiac care, have been suggested as contributing. No studies have been undertaken to determine if there are differences in access to and quality of cardiac care for First Nations compared to non-First Nations people. This study will determine if differences in cardiac care exist for First Nations compared to non-First Nations people by exploring access to specialized cardiac care and invasive cardiac procedures. It will also begin to address issues of quality of care by looking at differences in markers of quality care aimed at reducing the risk of vascular disease.
Research Characteristics
This project includes the following research characteristics:
Study Justification
"evaluate whether valacyclovir can delay the need for HAART initiation in HIV-infected individuals with asymptomatic HSV-2"
Novelty Statement
"first study to evaluate long-term clinical benefits of herpes suppression in HIV-HSV-2 co-infected individuals"
Methodology Innovation
evaluation of viral suppression strategy to delay HAART initiation